What happened
Telehealth providers Hims & Hers and Noom each launched peptide programs this week, saying they will write prescriptions for patients who qualify, STAT reported. The rollouts follow a move by the Department of Health and Human Services that lowered barriers for compounding pharmacies to supply peptide drugs, with BPC-157 cited as one example.
Synthetic peptides are short chains of amino acids. Once favored mainly by bodybuilders, some have drawn wider interest from consumers seeking more muscle, energy, libido or faster injury recovery. Many compounded versions sold to the public remain experimental. They lack Food and Drug Administration approval, and no randomized controlled trials have established their safety or effectiveness in people.
Smaller telehealth firms were already prescribing peptides. The entry of Hims, whose market capitalization exceeds $3.5 billion, and Noom, a privately held company valued at $3.7 billion, marks a notable step for the category in the US, according to the report.
Context
Interest in peptides has spread beyond bodybuilding circles into the broader wellness market. HHS has given the drugs prominence under Health Secretary Robert F. Kennedy Jr., who has openly championed peptides. Before this week, prescriptions for these compounds came mainly through smaller telehealth companies rather than the sector's biggest names.
The briefing
The week in tech, in one email.
The stories worth your time, every week. Unsubscribe anytime.
